SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-023364
Filing Date
2023-07-05
Accepted
2023-07-05 08:05:17
Documents
14
Period of Report
2023-07-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 44037
2 ex99-1.htm EX-99.1 21573
3 ex99-1_001.jpg GRAPHIC 4258
  Complete submission text file 0001493152-23-023364.txt   257842

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE dare-20230704.xsd EX-101.SCH 3033
5 XBRL LABEL FILE dare-20230704_lab.xml EX-101.LAB 34916
6 XBRL PRESENTATION FILE dare-20230704_pre.xml EX-101.PRE 22801
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3438
Mailing Address 3655 NOBEL DRIVE SUITE 260 SAN DIEGO CA 92122
Business Address 3655 NOBEL DRIVE SUITE 260 SAN DIEGO CA 92122 858-926-7655
Dare Bioscience, Inc. (Filer) CIK: 0001401914 (see all company filings)

IRS No.: 204139823 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36395 | Film No.: 231066706
SIC: 2834 Pharmaceutical Preparations